UnitedHealth, Change set Feb. 27 deadline to consummate merger 'Major blunder:' Ex-staffers blast Bristol Myers Squibb's handling of Breyanzi approval in latest CVR lawsuit update Kodiak's Eylea rival hits 'major disappointment' with failure in first of 6 phase 3 studies Smith & Nephew taps Siemens diagnostics head to replace outgoing CEO Teladoc stock faces turbulence with shrinking Q4 losses but modest 2022 guidance Novavax begins delivery of its long-delayed COVID-19 vaccine in Europe Roche's gene therapy unit finds a new Spark as co-founding CEO makes way for new leader Cardiovascular Systems plots moves into blood clot removal with development deal Gearing up for anemia market-grab against GSK—and maybe AZ—Akebia expands Vifor pact with $85M for key launch Sanofi, GSK post 58% efficacy in omicron-affected COVID-19 vaccine trial, teeing up race to regulators Cleerly’s AI scans comparable to gold-standard angiography in detecting heart disease: study Somatus clinches $325M-plus series E to expand its value-based kidney care model Featured Story | By Paige Minemyer The Department of Justice has less than a week to intervene in UnitedHealth Group's $8 billion acquisition of Change Healthcare, according to a Securities and Exchange Commission filing submitted last week. read more |
| |
|---|
|
Top Stories By Fraiser Kansteiner A slate of confidential witnesses have come forward to detail just how Bristol Myers dropped the ball on CAR-T drug Breyanzi's development. In a filing, they highlight the drugmaker’s myriad opportunities to rectify the situation before it was too late. read more By Kyle LaHucik Kodiak Sciences' attempt to rival Regeneron and Bayer's blockbuster drug Eylea, KSI-301, has flopped the first in a series of six phase 3 studies, casting an ominous cloud over the rest of the program. read more By Andrea Park A little over two years after taking on the top job at Smith & Nephew, CEO Roland Diggelmann is stepping down. read more By Rebecca Torrence Teladoc's stock has slumped since the telehealth giant posted its fourth-quarter 2021 earnings, despite beating Wall Street's projections on profit and revenue, as investors react to the company's lower-than-expected 2022 revenue guidance. read more By Kevin Dunleavy After much anticipation and several regulatory and manufacturing delays, the first doses of Novavax COVID-19 vaccine have departed a distribution site in The Netherlands, bound for Austria, France and Germany, the company said on Wednesday. read more By Kyle LaHucik Jeffrey Marrazzo, the co-founding CEO of Spark Therapeutics, will depart April 1 to make way for Chief Operating Officer Ron Philip. Philip will lead the Roche unit as it brings forward programs across hemophilia, Pompe disease, Huntington's and others. read more By Conor Hale The devicemaker has tapped Innova Vascular to assist in the development of both mechanical and aspiration-powered systems aimed at treating peripheral vascular disease, deep vein thrombosis and pulmonary embolisms. read more By Angus Liu Ahead of an FDA decision for its potential first-in-class anemia drug vadadustat, Akebia Therapeutics has expanded a licensing deal with Vifor Pharma. The deal puts Akebia in a better commercial situation before its possible rivalry against GlaxoSmithKline. read more By Nick Paul Taylor Sanofi and GlaxoSmithKline are nearly ready to seek approval for their COVID-19 vaccine. After suffering a delay late in 2020, the partners have linked two doses of the protein vaccine to 58% protection from symptomatic COVID-19 in a variant-affected phase 3 clinical trial. read more By Andrea Park Only a few months after it emerged from stealth and burst onto the medtech scene, Cleerly is already living up to its name. read more By Dave Muoio Already treating members in 34 states, the Virginia-based company said these funds will help expand its holistic kidney care model and reach more than 150,000 covered lives by the end of the year. read more | 